Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 8, 1997

View Archived Issues

Neose's NE-1530 enters phase I for otitis media

SangStat signs ciclosporin agreement with Amgen

Egis reports safe and effective new anxiolytic

Alcon compounds with dual antioxidant/cysteine prodrug properties

Structurally distinct class of 5-HT1B antagonists prepared at SmithKline Beecham

Analgesics under evaluation at Ortho

Egis prepares new AMPA receptor antagonists

Byk Gulden presents new PDE IV inhibitors

IL-12 for treatment of malignant tumors

Zeneca selects EGFR-TK inhibitor for clinical evaluation

IntraBiotics signs manufacturing and supply agreement for IB-367

HMR begins phase II trial with GA-EPO

Antiinflammatory and COX-2-inhibitory effects reported for rutaecarpine

Epstein-Barr virus vaccine enters phase I

Beneficial effects of PLA2 inhibitor in animal models of acute pancreatitis and ARDS

NeoTherapeutics: Q3 1997 highlights

Novel therapeutic for anxiety and depression enters phase I

Pharmacopeia and Bristol-Myers Squibb collaborate on chemokine receptors

SunPharm's anticancer drug completes phase I

MedImmune announces collaborations for MEDI-493

InSite Vision brings its once-daily glaucoma treatment to clinical trials

Another ANDA approval for Gensia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...